Health & Fitness
Health and Fitness
Health and Fitness
Wed, January 14, 2009
Tue, January 13, 2009
Cardima, Inc.: Cardima to Host Symposium at 45th Annual Meeting of the Society of Thoracic Surgeons and Showcase Products and T
FREMONT, CA--(Marketwire - January 13, 2009) - Cardima, Inc. (
At the STS conference, Cardima will sponsor a breakfast symposium, "Surgical Ablation - Keys to Success," highlighting the Company's Surgical Ablation System and featuring prominent physician speakers:
-- Li Poa, M.D., FACS, Chief of Cardiothoracic Surgery and Cardiac Surgery Program Director at Stamford Hospital and faculty member of Columbia University, who is among the world's leading authorities on surgical ablation for the treatment of atrial fibrillation (AF). Dr. Li Poa is head of the Cardima Center of Excellence and Training Program at Stamford Hospital. He has conducted extensive work perfecting thoracoscopic surgical techniques, and will train cardiothoracic surgeons in the use of the Cardima Surgical Ablation System. -- Dr. Sanjeev Saksena, MD, FHRS, FACC, FESC FAHA, Clinical Professor of Medicine, Robert Wood Johnson School of Medicine and Medical Director of the Electrophysiology Research Foundation, has been the Director of the Cardiovascular Institute, Atlantic Health System (Eastern Campus) from 1999- 2004 and is a Past President of the North American Society of Pacing and Electrophysiology (NASPE). He is the Founding editor and current Editor-in- Chief of the Journal of Interventional Cardiac Electrophysiology that recently published an entire issue devoted to surgical ablation of atrial fibrillation in December 2007. He has been and is a Planning/Steering Committee member of the National Institute of Health AFFIRM & TOPCAT trials that have focused on atrial fibrillation.
The breakfast symposium will be held at the San Francisco Marriott beginning on January 27 at 6:00 a.m. For additional details, please contact Dilyana Hadjeva at [ dilyana.hadjeva@cardima.com ]. Cardima products and technology will be on display on the exhibition floor at booth #414 at the STS conference, which is being held at the Moscone West Convention Center.
"Our presence at STS and our symposium featuring two preeminent physicians in the field of AF provide an opportunity to showcase our Surgical Ablation System with many thought-leaders, both nationally and internationally, who attend this meeting," said Cardima's CEO, Robert Cheney. "We also look forward to using this venue to support the Surgical Ablation System's adoption by creating awareness of the Cardima Surgical Program and supporting the domestic and international Cardima distributors that are attending STS. Additionally, Cardima will be conducting a sales training program that is being held in conjunction with the conference."
Cardima will also showcase its PATHFINDER® products and technology for diagnosing arrhythmias to the electrophysiology community at exhibition booth #706 at the International Boston Atrial Fibrillation Symposium, which is being held at the Seaport Hotel & Conference Center, The World Trade Center in Boston. The company will also hold sales force training programs in conjunction with this conference.
About Cardima Surgical Ablation System
The Surgical Ablation System uses Cardima's patented technology for the ablation of cardiac tissue. The System incorporates a microcatheter-based surgical probe coupled with Cardima's INTELLITEMP®, a radiofrequency energy management device. The probe incorporates irrigation, suction and illumination, which aid in placement and lesion depth. The Cardima Surgical Ablation System is able to create deep, long, linear and transmural cardiac lesions without gaps. The small, flexible design offers sole port-hole access, potentially decreasing procedure time, patient hospital stay and discomfort.
About Cardima PATHFINDER®
The Cardima PATHFINDER® and PATHFINDER® mini microcatheters allow entry into the most difficult and remote regions of the coronary vasculature. The small size, maneuverability, and flexibility differ from standard devices on the market.
About Atrial Fibrillation
Atrial fibrillation (AF) is the most common cardiac arrhythmia and a major concern for healthcare providers worldwide. AF symptoms typically include a rapid and irregular heartbeat, palpitations, discomfort and dizziness. During AF irregular, disorganized and quivering spasms of atrial tissue result in the heart's failure to pump adequate amounts of blood throughout the body. AF is a leading cause of stroke, can cause congestive heart failure and adds to the morbidity of any underlying heart disease. Recent estimates are that more than 2.5 million people in the U.S. have atrial fibrillation, of which 1 million are symptomatic yet do not respond well to drug therapy. The cause of AF is unknown and there is no variation by geography or ethnicity. The incidence of AF increases with age. Furthermore, about 200,000 new cases are diagnosed each year in the U.S.
About Cardima
Cardima, Inc. has developed the PATHFINDER®, TRACER™ and REVELATION® Series of diagnostic catheters, the VUEPORT® and NAVIPORT® Series of guiding catheters, the INTELLITEMP® Energy Management Device and the Surgical Ablation System. All of these Cardima devices have received CE mark approval and U.S. Food and Drug Administration (FDA) 510(k) clearance. The REVELATION® Series of ablation catheters with the INTELLITEMP® EP Energy Management Device, developed for the treatment of atrial fibrillation (AF), has received CE mark approval and is marketed in Europe.
PATHFINDER®, TRACER™, VUEPORT®, NAVIPORT®, REVELATION® and INTELLITEMP® are registered trademarks of Cardima, Inc.
Forward-Looking Statements
This press release may contain forward-looking statements. These statements are subject to risks and uncertainties. Investors are referred to the full discussion of risks and uncertainties associated with forward-looking statements as contained in our reports to the Securities and Exchange Commission, including our Forms 10-K and 10-Q. The Company assumes no obligation to update the forward-looking information.
